The FDA granted accelerated approval to the first medication for the treatment of metabolic dysfunction–associated steatohepatitis, resmetirom (Rezdiffra, Madrigal).
Resmetirom is approved for use in conjunction with diet and exercise for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2-F3 fibrosis).
“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said